Feedback

Induction and Adjuvant Therapy for Cancer of the Esophagus

Jelena Lukovic, Elena Elimova, Jonathan Yeung
Induction and Adjuvant Therapy for Cancer of the Esophagus is a topic covered in the Pearson's General Thoracic.

To view the entire topic, please or .

STS Cardiothoracic Surgery E-Book from The Society of Thoracic Surgeons provides expert guidance for Cardiac and Thoracic Surgery. Sections include Pearson’s General Thoracic, Esphageal, Adult Cardiac, and Pediatric and Congenital Cardiac Surgery. Explore these free sample topics:

-- The first section of this topic is shown below --

Key Points

  • Multimodality therapy is an important component of curative-intent treatment of cancer of the esophagus. The evidence on the optimal preoperative management is controversial, with some authors advocating for neoadjuvant chemotherapy and others advocating for concurrent chemotherapy and radiation therapy (CRT).
  • There are compelling data that neoadjuvant CRT followed by surgery has a survival benefit compared with surgery alone for patients with locally advanced or node positive disease.
  • There is level one evidence that adjuvant immunotherapy use following treatment with CRT for patients with non pathologic complete response improved disease free survival (DFS), whether this will translate into an overall survival benefit has yet to be determined.

-- To view the remaining sections of this topic, please or --

Key Points

  • Multimodality therapy is an important component of curative-intent treatment of cancer of the esophagus. The evidence on the optimal preoperative management is controversial, with some authors advocating for neoadjuvant chemotherapy and others advocating for concurrent chemotherapy and radiation therapy (CRT).
  • There are compelling data that neoadjuvant CRT followed by surgery has a survival benefit compared with surgery alone for patients with locally advanced or node positive disease.
  • There is level one evidence that adjuvant immunotherapy use following treatment with CRT for patients with non pathologic complete response improved disease free survival (DFS), whether this will translate into an overall survival benefit has yet to be determined.

There's more to see -- the rest of this entry is available only to subscribers.

Last updated: September 13, 2021